SCHEMBL629893

SCHEMBL629893

COC(=O)c1ccc2c(c1)[nH]c(=O)c1nc(SC)ncc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.56
CSNK2A1 P68400 2/20 0.56
KIF11 P52732 2/20 0.49
DYRK1A Q13627 1/20 0.48
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 3/20 0.43
HSD17B10 Q99714 2/20 0.43
PKM P14618 2/20 0.43
HTT P42858 2/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 2/20 0.42
GSK3B P49841 1/20 0.41
POLB P06746 1/20 0.41
PDGFRB P09619 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL630161 0.83 CSNK2A1 (0.57) PARP1CSNK2A1KIF11DYRK1AALDH1A1
SCHEMBL628532 0.79 PARP1 (0.67) PARP1CSNK2A1KIF11DYRK1AALDH1A1
SCHEMBL10131964 0.76 CSNK2A1 (0.52) CSNK2A1
SCHEMBL629427 0.76 CSNK2A1 (0.67) CSNK2A1ALDH1A1KMT2AKDM4EHSD17B10
SCHEMBL21995393 0.76 PARP1 (0.51) PARP1ALDH1A1KMT2AKDM4EHSD17B10
SCHEMBL25422100 0.75 PARP1 (0.68) PARP1CSNK2A1KIF11DYRK1AALDH1A1
SCHEMBL22057587 0.73 PARP1 (0.49) PARP1ALDH1A1KMT2AKDM4EHPGD
SCHEMBL1450481 0.73 CSNK2A2 (0.53) CSNK2A1ALDH1A1KMT2AHSD17B10HPGD
SCHEMBL4725998 0.73 KIF11 (0.84) PARP1CSNK2A1KIF11DYRK1AALDH1A1
SCHEMBL29708168 0.73 KIF11 (0.84) PARP1CSNK2A1KIF11DYRK1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584265-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2025-07-16 EP disclosed
WO-2024052690-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
WO-2024052690-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-03-14 WO disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
EP-2061765-B1 Serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES INC (TW) 2014-10-22 EP disclosed
EP-2061765-B1 Serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES INC (TW) 2014-10-22 EP disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
WO-2009097014-A2 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-08-06 WO disclosed
EP-2061765-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS Cylene Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS PACSIN2, CKS1B, CSNK1A1 PARP1 1797/4885CSNK2A1 6/4885KIF11 1251/4885
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885CSNK2A1 680/4885KIF11 2815/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 PARP1 3/4885CSNK2A1 24/4885KIF11 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.